Entera Bio Ltd. Banner Image

Entera Bio Ltd.

  • Ticker ENTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Entera Bio Ltd. Logo Image
  • 11-50 Employees
  • Based in Jerusalem, Israel
Entera is a leader in the development of orally delivered macromolecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variabilityMore, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
4.7 / 5.0 (169)

Entera Bio Ltd. reports have an aggregate usefulness score of 4.7 based on 169 reviews.

Entera Bio Ltd.

Most Recent Annual Report

Entera Bio Ltd.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Entera Bio Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!